The FDA recommends that sponsors, investigators and institutional review boards establish and implement policies and procedures to detail how they will manage clinical trial conduct and protect subjects during study disruptions. The policies and procedures may address many issues, including the informed consent process; which subjects can continue on the investigational produ... Read More